Detalhe da pesquisa
1.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Lancet
; 402(10411): 1449-1458, 2023 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696275
2.
Correlation Between Blue Fundus Autofluorescence and SD-OCT Measurements of Geographic Atrophy in Dry Age-Related Macular Degeneration.
Am J Ophthalmol
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719131
3.
Vision loss reduction with avacincaptad pegol for geographic atrophy: a 12-month post hoc analysis of the GATHER1 and GATHER2 trials.
Ophthalmol Retina
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719191
4.
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Eye (Lond)
; 37(17): 3551-3557, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964259
5.
Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
Ophthalmol Retina
; 4(1): 57-66, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31902472
6.
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Eye (Lond)
; 37(17): 3705, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237234
7.
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Sci Transl Med
; 8(321): 321ra5, 2016 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26764156